• India has the highest number of USFDA-approved plants outside USA 

  • Indian healthcare market is the world's second-fastest growing with a market of US$65 billion growing at 15% CAGR 

  • India's medical tourism sector is growing at a rate of 30%, making it a $2 billion industry by 2015. 


Visalakshi Chandramouli

Partner, Tata Capital Healthcare Fund

Visalakshi Chandramouli is the Founding Partner of Tata Capital Healthcare Fund, an India dedicated Healthcare & Life Sciences Private Equity Fund. She has spent over two decades across Healthcare Private Equity, Equity Research and Pharmaceutical R&D operations.

Visalakshi presently heads the Tata Capital Healthcare Fund and drives the fund raising and investment management activities of the fund. She has successfully led the fund raise of Tata Capital Healthcare Fund with commitments from global investor base as well as deployment of the fund commitments. She is actively involved in portfolio management through presence on Board and other committees of Investee companies. Chandramouli started her career as a research scientist at Cipla, a global pharmaceutical company and thereafter, spent over 12 years as Lead Healthcare investment analyst at leading financial services firms like Kotak Securities and Merrill Lynch where she was Senior Director of India Healthcare Equity Research and rated No. 2 in Asia for Healthcare for 2008 on the prestigious Institutional Investor (II) poll rankings (rated No. 3 in 2007).

Visalakshi brings on board a deep experience of technical skills within the pharmaceutical industry as well as commercial & investment experience in the industry. In her previous two roles at DSP Merrill Lynch and Kotak Securities for close to a decade, she had been involved in executing IPO/ADS transactions aggregating to value of ~US$400 million for Indian pharmaceutical companies. In her present role, apart from sourcing, and execution of private equity transactions for the Fund, Visalakshi has been responsible for creating an ecosystem of active operating advisors and drive value-addition initiatives for the Fund's portfolio companies.

Visalakshi is a Chemical Technologist from ICT Mumbai (specialization in pharmaceuticals & fine chemicals) and MBA (finance) from Mumbai University. She is a graduate in Advanced Management Program (AMP) from the Harvard Business School. In 2015, Visalakshi certified as TBEM (Tata Business Excellence Model) External Assessor for Tata Group Companies. Visalakshi has been nominated by FICCI (The Federation of Indian Chambers of Commerce and Industry) for the 'Women on Corporate Boards' Mentorship program.


Vamesh Chovatia

Partner, Tata Capital Healthcare Fund

Vamesh joined Tata Capital in March 2015 as Partner of the Tata Capital Healthcare Fund. He has over 25+ years of experience in investment banking and private equity advisory. His experience spans managing investments and advising businesses across multiple industries. Vamesh co-lead's the healthcare fund team and will be actively involved in managing the full lifecycle of new fundraising, investing, portfolio management and divestments.

Prior to joining Tata Capital, Vamesh was the Managing Director of New Enterprise Associates (India) Pvt. Ltd.(NEA), an affiliate of US based venture capital firm and he was focused on investing in Pharma and Lifesciences sectors where he led investments in a company engaged in manufacturing of radiation therapy equipment and a company developing digital medical education courseware.

Prior to joining NEA, he served as a Director, Kotak Private Equity Group, where he was responsible for originating transactions and investing in several companies across a wide variety of sectors viz. Logistics, Retail, Infrastructure, Financial Services apart from Life Sciences and Pharmaceuticals. During his stint with Kotak, he has experienced a full life cycle of successful fund raising, investing and exiting businesses.

Prior to his stint with Kotak, Vamesh worked with leading investment banks such as Enam Financial, ICICI Securities, Prime Securities, Standard Chartered Bank and Canbank. For a large part of his career, he has focused on private equity advisory and has successfully structured transactions across multiple sectors including IT and ITES, media and entertainment, healthcare, retailing, logistics, telecom, textiles, and oil and gas related services.

Vamesh holds a Post Graduate degree in Business Management from Symbiosis Institute of Business Management and is a Commerce graduate from Mumbai University.


Swati Bhartia, CFA

Vice President, Tata Capital Healthcare Fund

Swati joined Tata Capital in March 2014 with around nine years of experience in private equity investments and equity research domain.

Before joining Tata Capital she was working with Oman India Joint Investment Fund (OIJIF), a sector agnostic sovereign fund jointly set-up by State Bank of India and Oman's State General reserve Fund. She was involved in deal evaluation, execution and monitoring investments in diverse sectors such as healthcare, machine tools, auto ancillaries, specialty chemicals and pharmaceuticals.

Prior to that, Swati worked with Eredene Capital (an AIM listed PE fund), where she managed US$50 Mn portfolio spread across four companies. She started her career with Crisil as equity Research Analyst in 2005, covering European mid & large-cap Biotech companies.

Swati is a 37th rank-holder Chartered Accountant and a CFA charter-holder.



Sandeep Lal

Vice President, Tata Capital Healthcare Fund

Sandeep Lal has ten years of Private Equity advisory and Merger & Acquisition experience across early to late stage deals. He has worked in sectors such as healthcare, logistics, transportation, e-commerce and consumer.

Sandeep Lal has ten years of Private Equity advisory and Merger & Acquisition experience across early to late stage deals. He has worked in sectors such as healthcare, logistics, transportation, e-commerce and consumer. Sandeep joined Tata Capital Healthcare Fund in 2016 as Vice President and drives the investment assessment, transaction management, fund raising, post investment and exit management activities at the fund.

Prior to Joining Tata Capital Healthcare Fund, Sandeep has spent 9 years with firms like Alvarez and Marsal, KPMG and Evalueserve. During this period, he has worked across investment assessment, deal life cycle support, fund raising, operations management, revenue improvement, cost management and margin expansion programs. His experience is spread across six countries world-wide and has advised more than 50 funds and corporates in India. Sandeep also brings deep experience of commercial evaluation of investment from his roles in Alvarez and Marsal, KPMG and Evalueserve. In these organizations, he worked across healthcare. e-commerce, transportation and logistics industries. He has worked on transactions worth $ 3 billion including medical devices, hospital chains, health insurance and pharmaceutical product distribution.

Sandeep started his career as a management trainee at ICICI Prudential life insurance focusing to sell health insurance policies in Delhi/NCR, India. Towards the end of his stint, he was managing a sales team of about 250 on ground agents across multiple offices. Sandeep hold a Bachelors in Technology from Indian Institute of Technology, Delhi and a Masters in Business Management from Indian Institute of Management, Lucknow.





Tata Capital Private Equity has engaged CAMS - a professionally managed, institutionally owned and SEBI regulated IT services solution partner to provide investor related accounting services.

To log in to your CAMS Online Account, click here


Fund in the news
  • Tata Capital Healthcare Fund plans Fund II in 2016 Know more
  • Tata Capital Healthcare Fund looking to raise second fund next year Know more
Portfolio News & Articles
  •   Robotic technique all set to be a game changer in knee surgeries Know more
  •   56-yr-old undergoes rare robotic knee replacement surgery in city Know more
  •   Phase I/II trials for DFU potential drug successful: NovaLead Know more
  •   NovaLead Pharma to launch drug for diabetic foot ulcer Know more